Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

529.14 +10.87 (+2.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 432,111
Open 525.47
Bid (Size) 500.00 (40)
Ask (Size) 550.02 (40)
Prev. Close 518.27
Today's Range 522.04 - 535.77
52wk Range 302.19 - 609.35
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play ↗
Via Chartmill

Performance

YTD
+6.5%
+6.5%
1 Month
-0.0%
-0.0%
3 Month
-6.6%
-6.6%
6 Month
+9.7%
+9.7%
1 Year
+68.5%
+68.5%

More News

Read More
News headline image
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
United Therapeutics (NASDAQ:UTHR) Tumbles as Q2 Revenue Misses Despite EPS Beat ↗
Via Chartmill
News headline image
UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures
Via StockStory
News headline image
United Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
Earnings To Watch: United Therapeutics (UTHR) Reports Q2 Results Tomorrow
Via StockStory
News headline image
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Acquires Thymmune Therapeutics
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
From United Therapeutics Corporation
Via Business Wire
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
Via StockStory
Topics Artificial Intelligence
News headline image
Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
These 3 Stocks Lowered Their Share Counts Drastically in Q1 ↗
Via MarketBeat
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
Via StockStory
Topics Energy
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down
Via StockStory
Topics Credit Cards
News headline image
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
From United Therapeutics Corporation
Via Business Wire

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 529.14
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 08/19/26 04:00 PM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 23.75B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 24B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.